Scopolamine

Administration

• Type: Anticholinergics
• Dosage Forms:
• Routes of Administration: scopolamine- transdermal. Scopolamine hydrobromide- IV, oral, Ophthalmic
• Common Trade Names:

Adult Dosing

• 0.32-0.1mg IV/IM/SubQ
• 0.4-0.8mg PO
• 1-2 drops (0.25% ophthalmic solution) up to 4 times daily
• 1 transdermal patch q72h (each 1.5mg patch delivers 1mg scopolamine over 72h)

Pediatric Dosing

• Sedation:
  • 6mo-3y: 0.1-0.15 mg IM/IV/subQ
  • 3-6y: 0.2-0.3 mg IM/IV/subQ
• Vomiting: 6 mcg/kg subQ
• Transdermal patch not FDA-approved for children

Special Populations

• Pregnancy Rating: C
• Lactation risk: infant risk is minimal
• Renal dosing: contraindicated in renal impairment
• Hepatic dosing: contraindicated in hepatic impairment

Contraindications

• Allergy to class/drug
• Glaucoma
• Chronic lung disease (repeated doses)
• Prostatic hypertrophy
• Pyloric obstruction

Adverse Reactions

Serious

• Tachyarrhythmia
• Hallucinations, confusion
• Glaucoma
• Systemic absorption of ophthalmic formulation

Common

• Dry skin, diminished sweating
• Xerostomia
• Amnesia, somnolence
• Mydriasis, blurred vision
• Local irritation

Pharmacology

• Half-life: 9.5h (transdermal)
• Metabolism:
• Excretion:

Mechanism of Action

• Belladonna alkaloid with anticholinergic (predominantly antimuscarinic) properties

See Also

• Anticholinergic toxicity

References

Authors

Claire